Tidutamab  (Synonyms: 泰妥单抗; XmAb-18087)

Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC)^[1].

half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3

Chimeric; Humanized

Tidutamab (XmAb-18087; 0-100000 ng/mL)与人 SSTR2+ CHO 细胞结合，ED₅₀ 值为 2.2 μg/mL，并介导 T 细胞杀伤 SSTR2+ 靶细胞^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Tidutamab (XmAb-18087; 3 mg/kg; i.p.; 单次注射) 在 NSG 小鼠中刺激人 T 细胞杀伤 SSTR2+ A549 肺癌肿瘤^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2148354-90-7

泰妥单抗

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  half-IGG1-kappa/(scFv-heavy-lambda)-h-CH2-CH3

• [1]. Hyung LS, et, al. Anti-SSTR2 × anti-CD3 bispecific antibody induces potent killing of human tumor cells in vitro and in mice, and stimulates target-dependent T cell activation in monkeys: A potential immunotherapy for neuroendocrine tumors. Cancer Res (2017) 77 (13_Supplement): 3633.